Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
D 50.79 -0.29% -0.15
VCEL closed down 0.29 percent on Friday, October 15, 2021, on 58 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Nov 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical VCEL trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
200 DMA Resistance Bearish -0.29%
50 DMA Resistance Bearish -0.29%
Crossed Above 20 DMA Bullish -0.29%
Pocket Pivot Bullish Swing Setup -0.29%
Spinning Top Other -0.29%
Bollinger Band Squeeze Range Contraction -0.29%
Older End-of-Day Signals for VCEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Vericel Corporation Description

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cells Heart Failure Cell Therapy Knee Burns Myopathy Cardiomyopathy Cartilage Dilated Cardiomyopathy Osteochondritis Dissecans Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 68.93
52 Week Low 18.09
Average Volume 316,579
200-Day Moving Average 51.24
50-Day Moving Average 50.98
20-Day Moving Average 49.61
10-Day Moving Average 50.33
Average True Range 2.19
ADX 11.99
+DI 21.18
-DI 16.91
Chandelier Exit (Long, 3 ATRs) 46.03
Chandelier Exit (Short, 3 ATRs) 53.08
Upper Bollinger Bands 52.02
Lower Bollinger Band 47.19
Percent B (%b) 0.75
BandWidth 9.73
MACD Line -0.31
MACD Signal Line -0.50
MACD Histogram 0.1907
Fundamentals Value
Market Cap 2.31 Billion
Num Shares 45.4 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio 16930.00
Price-to-Sales 9.59
Price-to-Book 9.99
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.87
Resistance 3 (R3) 52.97 52.37 52.52
Resistance 2 (R2) 52.37 51.84 52.32 52.41
Resistance 1 (R1) 51.58 51.52 51.29 51.48 52.29
Pivot Point 50.99 50.99 50.84 50.94 50.99
Support 1 (S1) 50.20 50.46 49.90 50.10 49.29
Support 2 (S2) 49.60 50.13 49.55 49.17
Support 3 (S3) 48.81 49.60 49.06
Support 4 (S4) 48.71